

1
2
3
4
5
6

Supplementary Materials

Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19

7 **Supplementary Table 1:** Clinical and demographic characteristics of patients with COVID-19
 8 who did or did not develop VAP at the “early” and “late” timepoints, and control patients who were
 9 intubated without LRTI, included in the bulk RNA sequencing primary analysis.

10

	VAP (early timepoint)	No-VAP (early timepoint)	P-value (early - VAP vs No-VAP)	VAP (late timepoint)	No-VAP (late timepoint)	P-value (late - VAP vs No-VAP)	Controls (early timepoint)	P-value (+/- COVID-19)
N	4	8		5	8		8	
Age in years, median (IQR)	59.5 (56.0, 66.0)	49 (40.5, 64.0)	0.268	51.0 (48.0, 53.0)	59.5 (47.0, 64.5)	0.271	63.0 (36.0, 79.0)	0.642
Female (%)	1 (25.0%)	3 (37.5%)	1.00	2 (40.0%)	4 (50.0%)	1.00	4 (50.0%)	0.648
Race (%)								
Black	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	-
Asian	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	1 (12.5%)	1.00	1 (12.5%)	0.400
White	0 (0.0%)	2 (25.0%)	0.515	1 (20.0%)	2 (25.0%)	1.00	7 (87.5%)	<0.01
Other	4 (100.0%)	5 (62.5%)	0.491	4 (80.0%)	5 (62.5%)	1.00	0 (0.0%)	<0.01
Multiple	0 (0.0%)	1 (12.5%)	1.00	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	1.00
Hispanic ethnicity (%)	3 (75.0%)	4 (50.0%)	0.576	4 (80.0%)	4 (50.0%)	0.565	1 (12.5%)	0.070
Comorbidities (%)								
Autoimmune	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	1 (12.5%)	1.00	2 (25.0%)	0.147
Cancer	0 (0.0%)	0 (0.0%)	-	1 (20.0%)	0 (0.0%)	0.385	1 (12.5%)	0.400
COPD/Asthma	0 (0.0%)	2 (25.0%)	0.515	2 (40.0%)	1 (12.5%)	0.510	0 (0.0%)	0.495
DM	4 (100.0%)	3 (37.5%)	0.081	3 (60.0%)	4 (50.0%)	1.00	3 (37.5%)	0.650
HTN	3 (75.0%)	1 (12.5%)	0.067	2 (40.0%)	1 (12.5%)	0.510	4 (50.0%)	0.648
Obesity	4 (100.0%)	5 (62.5%)	0.491	4 (80.0%)	4 (50.0%)	0.565	3 (37.5%)	0.167
Solid organ transplant	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	-
Baseline IS meds (%)	0 (0.0%)	0 (0.0%)	-	1 (20.0%)	1 (12.5%)	1.00	1 (12.5%)	0.400
Treated with immunosuppressants (%)	2 (50.0%)	3 (42.9%)*	1.00	5 (100.0%)	4 (57.1%)*	0.205	2 (25.0%)	0.633
Steroid days before sample, median (IQR)	1.5 (0.0, 3.5)	0.0 (0.0, 1.5)	0.343	9.0 (7.5, 16.5)	0.0 (0.0, 4.0)	0.013	0.0 (0.0, 0.5)	0.497
Antibiotic use before sample (%)	4 (100%)	8 (100%)	-	5 (100%)	8 (100%)	-	7 (87.5%)	0.400
Length of stay, days, median (IQR)	57.5 (44.5, 65.6)	19.0 (17.0, 34.5)	0.017	34.0 (28.0, 38.0)	24.0 (17.0, 34.5)	0.213	10.5 (6.0, 19.5)	<0.01
Duration of mechanical ventilation, days, median (IQR)	22.5 (19.0, 27.0)	14.0 (5.0, 23.5)	0.174	18.0 (7.0, 25.0)	6.5 (2.5, 16.0)	0.271	11.0 (11.0, 14.0)	0.151
Vasopressors^a (%)	4 (100.0%)	7 (87.5%)	1.00	5 (100.0%)	8 (100.0%)	-	4 (50.0%)	0.023
ECMO^b (%)	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	-
WHO Severity Score^c, median (IQR)	7 (7, 7.5)	7 (7, 7)	0.151	7 (7, 8)	7 (7, 7)	0.062	-	-
Mortality (%)	1 (25.0%)	0 (0.0%)	0.333	2 (40.0%)	0 (0.0%)	0.128	1 (12.5%)	1.00
Days before VAP (median [range])	16.5 (15, 38)	-	-	2 (2, 3)	-	-	-	-
Days post intubation (median [range])	2 (1, 5)	2 (1, 4)	0.930	17 (8, 23)	9 (6, 19)	0.160	1 (1, 3)	0.062

11 *Immunosuppressant use unknown for one No-VAP patient due to enrollment in a double-blinded clinical trial; N of 7 used
 12 ^a Defined as any requirement for vasopressors during admission
 13 ^b Defined as ever requiring ECMO during admission
 14 ^c Defined as maximum value for World Health Organization Ordinal Scale for Clinical Improvement during admission
 15 P-values represent comparisons of patients with or without VAP at the early or late timepoint, or all COVID-19 patients at the early timepoint
 16 compared to intubated controls. Statistical significance was determined using Fisher’s exact test (categorical variables) or by Wilcoxon test
 17 (continuous variables). Abbreviations: COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; ECMO: extracorporeal
 18 membrane oxygenation; HTN: hypertension; IQR: interquartile range; IS: immunosuppressive; VAP: ventilator-associated pneumonia; WHO:
 19 World Health Organization

20 **Supplementary Table 2:** Clinical and demographic characteristics of patients with COVID-19
 21 who do or do not develop VAP at the “early” and “late” timepoints who were included in the
 22 single cell RNA sequencing analysis.

	VAP (early timepoint)	No-VAP (early timepoint)	P-value (early - VAP vs No-VAP)	VAP (late timepoint)	No-VAP (late timepoint)	P-value (late - VAP vs No-VAP)
N	4	6		4	4	
Age in years, median (IQR)	64.0 (50.5, 76.5)	56.5 (47.0, 68.0)	0.392	61.5 (37.5, 74.0)	60.0 (50.5, 74.0)	0.271
Female (%)	2 (50.0%)	2 (33.3%)	1.00	0 (0.0%)	2 (50.0%)	0.429
Race (%)						
Black	0 (0.0%)	1 (16.7%)	1.00	0 (0.0%)	1 (25.0%)	1.00
Asian	0 (0.0%)	0	-	0 (0.0%)	0 (0.0%)	-
White	0 (0.0%)	2 (33.3%)	0.467	1 (25.0%)	1 (25.0%)	1.00
Other	4 (100.0%)	3 (50.0%)	0.200	3 (75.0%)	2 (50.0%)	1.00
Hispanic ethnicity (%)	4 (100.0%)	2 (33.3%)	0.076	4 (100.0%)	2 (50.0%)	0.429
Comorbidities (%)						
Autoimmune	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	0 (0.0%)	-
Cancer	2 (50.0%)	0 (0.0%)	0.133	1 (25.0%)	0 (0.0%)	1.00
COPD/Asthma	0 (0.0%)	2 (33.3%)	0.467	1 (25.0%)	2 (50.0%)	1.00
DM	1 (25.0%)	3 (50.0%)	0.571	2 (50.0%)	2 (50.0%)	1.00
HTN	1 (25.0%)	1 (16.7%)	1.00	2 (50.0%)	3 (75.0%)	1.00
Obesity	1 (25.0%)	3 (50.0%)	0.571	2 (50.0%)	3 (75.0%)	1.00
Solid organ transplant	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	1 (25.0%)	1.00
Baseline IS meds (%)	1 (25.0%)	0 (0.0%)	0.400	0 (0.0%)	1 (25.0%)	1.00
Treated with immunosuppressants (%)	4 (100.0%)	2 (33.3%)	0.076	4 (100.0%)	3 (75.0%)	1.00
Steroid days before sample, median (IQR)	1 (1, 7)	0 (0, 1)	0.170	5.5 (2.5, 6.5)	8.5 (3.5, 10)	0.240
Antibiotic use before sample (%)	4 (100.0%)	6 (100.0%)	-	4 (100.0%)	4 (100.0%)	-
Length of stay, days, median (IQR)	33.0 (25.5, 38.0)	29.0 (18.0, 37.0)	0.521	38.0 (28.5, 113.5)	27.0 (23.5, 30.0)	0.245
Duration of mechanical ventilation, days, median (IQR)	20.0 (14.0, 23.5)	10.5 (7.0, 19.0)	0.286	23.5 (14.5, 29.5)	10.5 (7.0, 25.0)	0.564
Vasopressors^a (%)	4 (100.0%)	6 (100.0%)	-	4 (100.0%)	4 (100.0%)	-
ECMO^b (%)	0 (0.0%)	0 (0.0%)	-	0 (0.0%)	0 (0.0%)	-
WHO Severity Score^c, median (IQR)	8 (7.5, 8)	7 (7, 7)	0.016	7 (7, 7.5)	7 (7, 7)	0.317
Mortality (%)	3 (75.0%)	0 (0.0%)	0.033	1 (25.0%)	0 (0.0%)	1.00
Days before VAP, median (range)	9.5 (8, 16)	-	-	3 (2, 4)	-	-
Days after intubation, median (range)	5.5 (1, 10)	4.0 (2, 13)	0.748	8.5 (7, 18)	10.5 (4, 15)	0.884

23 *Immunosuppressant use unknown for one No-VAP patient due to enrollment in a double-blinded clinical trial; N of 7 used

24 ^a Defined as any requirement for vasopressors during admission

25 ^b Defined as ever requiring ECMO during admission

26 ^c Defined as maximum value for World Health Organization Ordinal Scale for Clinical Improvement during admission

27 P-values represent comparisons of patients with or without VAP at the early or late timepoint, or all COVID-19 patients at the early timepoint
 28 compared to intubated controls. Statistical significance was determined using Fisher’s exact test (categorical variables) or by Wilcoxon test
 29 (continuous variables). Abbreviations: COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; ECMO: extracorporeal
 30 membrane oxygenation; HTN: hypertension; IQR: interquartile range; IS: immunosuppressive; VAP: ventilator-associated pneumonia; WHO:
 31 World Health Organization


32 **Supplementary Table 3:** Details of immunosuppressant use for patients included in the primary
 33 bulk and single-cell RNA sequencing analyses at both “early” and “late” timepoints.
 34

Patient ID	Analysis	Group	IS before sample	Immunosuppressant details	Steroid days
1059	Bulk RNA-seq	VAP-early	N	-	0
1154	Bulk RNA-seq	VAP-early	Y	Dexamethasone 6 mg daily	4
1196	Bulk RNA-seq	VAP-early	N	-	0
1254	Bulk RNA-seq	VAP-early	Y	Dexamethasone 6 mg daily	3
1001	Bulk RNA-seq	No-VAP-early	N	-	0
1002	Bulk RNA-seq	No-VAP-early	N	-	0
1072	Bulk RNA-seq	No-VAP-early	N	-	0
1115	Bulk RNA-seq	No-VAP-early	N	-	0
1136	Bulk RNA-seq	No-VAP-early	Y	Betamethasone 12 mg x 1	1
1158	Bulk RNA-seq	No-VAP-early	Unknown*	Baricitinib vs placebo*	0
1185	Bulk RNA-seq	No-VAP-early	Y	Dexamethasone 6 mg daily	2
1223	Bulk RNA-seq	No-VAP-early	Y	Dexamethasone 6 mg daily	2
227	Bulk RNA-seq	Control	N	-	0
413	Bulk RNA-seq	Control	N	-	0
414	Bulk RNA-seq	Control	N	-	0
462	Bulk RNA-seq	Control	N	-	0
473	Bulk RNA-seq	Control	N	-	0
477	Bulk RNA-seq	Control	Y	Dexamethasone 0.5 mg daily, fludrocortisone 0.1 mg daily	1
555	Bulk RNA-seq	Control	N	-	0
563	Bulk RNA-seq	Control	Y	Dexamethasone 10 mg x1, then 4 mg q6 hours	5
1047	Bulk RNA-seq	VAP-late	Y	Methylprednisolone 40 mg IV q6, tapered over 6 days to home dexamethasone 4 mg daily	23
1154	Bulk RNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	7
1172	Bulk RNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	8
1196	Bulk RNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	10
1233	Bulk RNA-seq	VAP-late	Y	Hydrocortisone 100 mg IV q8, tapered over 1-7 days [#] ; tocilizumab x1	1-7 [#]
1001	Bulk RNA-seq	No-VAP-late	Y	Prednisone 50 mg x 1	1
1002	Bulk RNA-seq	No-VAP-late	N	-	0
1038	Bulk RNA-seq	No-VAP-late	Y	Tocilizumab x 2	0

1072	Bulk RNA-seq	No-VAP-late	N	-	0
1115	Bulk RNA-seq	No-VAP-late	N	-	0
1158	Bulk RNA-seq	No-VAP-late	Unknown*	Baricitinib vs placebo*	0
1185	Bulk RNA-seq	No-VAP-late	Y	Dexamethasone 6 mg daily	8
1244	Bulk RNA-seq	No-VAP-late	Y	Dexamethasone 6 mg daily	7
1047	scRNA-seq	VAP-early	Y	Methylprednisolone 40 mg IV q 6 hours, tapered over 6 days to home dexamethasone 4 mg daily	9
1154	scRNA-seq	VAP-early	Y	Dexamethasone 6 mg daily	9
1161	scRNA-seq	VAP-early	Y	Dexamethasone 10 mg x 1, then 6 mg daily; baricitinib vs placebo	4
1357	scRNA-seq	VAP-early	Y	Dexamethasone 6 mg daily	1
1001	scRNA-seq	No-VAP-early	N	-	0
1002	scRNA-seq	No-VAP-early	N	-	0
1072	scRNA-seq	No-VAP-early	N	-	0
1115	scRNA-seq	No-VAP-early	N	-	0
1158	scRNA-seq	No-VAP-early	Unknown*	Baricitinib vs placebo*	0
1271	scRNA-seq	No-VAP-early	Y	Dexamethasone 6 mg daily; canakinumab vs placebo	10
1154	scRNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	7
1233	scRNA-seq	VAP-late	Y	Hydrocortisone 100 mg IV q8 hours, tapered over 1-7 days #; tocilizumab x1	1-7#
1264	scRNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	10
1357	scRNA-seq	VAP-late	Y	Dexamethasone 6 mg daily	6
1072	scRNA-seq	No-VAP-late	N	-	0
1271	scRNA-seq	No-VAP-late	Y	Dexamethasone 6 mg daily; canakinumab vs placebo	10
1290	scRNA-seq	No-VAP-late	Y	Dexamethasone 6 mg daily; canakinumab vs placebo	7
1320	scRNA-seq	No-VAP-late	Y	Dexamethasone 6 mg daily x 10 days, then home prednisone 5mg daily; home tacrolimus; home mycophenolate mofetil	12


35
36
37

*Unknown due to enrollment in double-blinded clinical trial of baricitinib vs placebo. # Exact duration unknown to due to incomplete records on transfer from an outside facility. Abbreviations: IS = immunosuppressive.



38
39
40
41


Supplementary Figure 1: Principal component analysis (PCA) plot of all samples included in bulk RNA-seq analyses.




42
 43
 44
 45
 46
 47
 48
 49
 50

Supplementary Figure 2: Regulation of cytokines at the “early” timepoint with respect to a baseline of uninfected, intubated controls. IPA upstream regulator analysis was based on differential gene expression analyses of patients with VAP vs controls and No-VAP patients vs controls. Cytokines were selected from the IPA results if they had a Z-score absolute value > 2 and an overlap P-value < 0.05 in both of the comparisons (VAP vs controls and No-VAP vs controls). All cytokines are tabulated in Supplementary Data File 3.

51 A




B



52
53

54 **Supplementary Figure 3:** SARS-CoV-2 viral load in VAP and No-VAP patients at the “early”
55 timepoint. Viral load was quantified by **A)** reads per million (rpM) from bulk RNA-seq and **B)** cycle
56 threshold (Ct) values by qPCR for the SARS-CoV-2 N gene. The Ct value for one sample in the
57 No-VAP group was not determined. Bar plots represent the median with interquartile range.
58 Statistical significance was determined by Mann-Whitney tests.

59




60
61
62
63
64
65
66


Supplementary Figure 4: UMAPs of all single cell RNA-seq samples, annotated by **(A)** low-resolution cell type and **(B)** high-resolution cell type. **(C)** Expression of marker genes used for annotation. UMAPs of all samples annotated by **(D)** timepoint and **(E)** sample. **(F)** UMAP of all samples at the “early” timepoint, annotated by VAP status. **(G)** Cell type proportions in VAP and No-VAP samples at the “early” timepoint. Mann-Whitney tests were conducted to determine statistical significance. None of the cell types reached statistical significance with $P < 0.05$.

Alveolar macrophages


A



B




C




67
68
69
70
71
72
73
74
75

Supplementary Figure 5: (A) Volcano plot displaying the differentially expressed genes between VAP and No-VAP patients in alveolar macrophages at the “early” timepoint. **(B-C)** Ingenuity Pathway Analysis (IPA) of (B) canonical pathways and (C) upstream cytokine activation states based on differential gene expression in alveolar macrophages of patients who developed VAP versus those who did not, including genes with adjusted P-values < 0.05. Only significant pathways and cytokines (IPA Z-score absolute value > 2 and overlap P-value < 0.05) are depicted. All pathways are provided in Supplementary Data File 5.


A Late timepoint




B



C




D




Monocytes/macrophages

E




F



76
77

78 **Supplementary Figure 6:** UMAP of single cell RNA-seq samples at the “late” timepoint,
79 annotated by (A) cell type, (B) sample, or (C) VAP status. (D) Cell type proportions in VAP and
80 No-VAP samples at the “late” timepoint. Mann-Whitney tests were conducted to determine
81 statistical significance. None of the cell types reached statistical significance with $P < 0.05$. (E-F)


82 Ingenuity Pathway Analysis (IPA) of (E) canonical pathways and (F) upstream cytokine activation
83 states based on differential gene expression in monocytes/macrophages of patients who
84 developed VAP versus those who did not at the “late” timepoint, including genes with adjusted P-
85 values < 0.05. Only significant pathways (IPA Z-score absolute value > 2 and overlap P-value
86 <0.05) are depicted. All pathways are provided in Supplementary Data File 5.



88

89

90 **Supplementary Figure 7:** Gene set enrichment analysis (GSEA) comparing patients who did not
 91 develop VAP at the “early” (green) versus “late” (red) timepoints. GSEA results were considered
 92 significant with an adjusted P-value < 0.05. All pathways are provided in Supplementary Data File
 93 2.




95

96

97 **Supplementary Figure 8:** Pathway expression for samples at the “early” timepoint, comparing
 98 patients who were treated with immunosuppressants before sample collection and those who
 99 were not. Pathway Z-scores for **(A)** the innate immune system pathway and **(B)** the adaptive
 100 immune system pathway were calculated by averaging Z-scores for the top 20 leading edge
 101 genes of each pathway. Samples from VAP patients are shown in blue, No-VAP patients are
 102 shown in green. IS = treated with immunosuppressants. Plots represent the mean with standard
 103 deviation. Statistical significance was determined by t-test.

104



105
 106
 107
 108
 109
 110

Supplementary Figure 9: Lung microbiome β -diversity (Bray Curtis Index, NMDS scaling) in COVID-19 patients with relation to VAP development over time by days since intubation.

111 **Supplementary Data Files**

112

113 **Data File S1:** Differentially expressed genes from bulk RNA-seq analyses.

114 **Data File S2:** Gene set enrichment analysis results from bulk RNA-seq analyses. NES =
115 Normalized enrichment score.

116 **Data File S3:** Ingenuity pathway analysis for upstream regulating cytokines from bulk RNA-seq
117 analyses.

118 **Data File S4:** Differentially expressed genes from single cell RNA-seq analyses.

119 **Data File S5:** Ingenuity pathway analysis for canonical pathways from single cell RNA-seq
120 analyses.

121 **Data File S6:** Ingenuity pathway analysis for upstream regulating cytokines from single cell RNA-
122 seq analyses.

123 **Data File S7:** Abundance of top respiratory microbes detected in each patient at the early and
124 late timepoints.

125 **Data File S8:** Detailed clinical and demographic data for patients in this study.

126

127 **Supplementary Appendix:** COMET Consortium Member list.